Repare Therapeutics Inc. (RPTX)
NASDAQ: RPTX · Real-Time Price · USD
1.011
-0.039 (-3.71%)
Mar 31, 2025, 1:12 PM EDT - Market open
Repare Therapeutics Revenue
In the year 2024, Repare Therapeutics had annual revenue of $53.48M with 4.58% growth.
Revenue (ttm)
$53.48M
Revenue Growth
+4.58%
P/S Ratio
0.83
Revenue / Employee
$414,550
Employees
129
Market Cap
42.98M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RPTX News
- 23 days ago - Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 2 months ago - Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions - Business Wire
- 3 months ago - Why Is Repare Therapeutics Stock Trading Lower On Friday? - Benzinga
- 3 months ago - Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - Business Wire
- 3 months ago - Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - Business Wire
- 4 months ago - Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - Business Wire
- 5 months ago - Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results - Business Wire